
A gene therapy that tweaks the immune system might offer hope to people with blood cancer that has resisted standard treatments, a new preliminary trial suggests. The cancer, called multiple myeloma, arises in certain white blood cells. It is currently incurable, but there are treatments that can help people live with the disease for years. However, most people eventually progress, and some fail to respond to the available therapies at all. The new study involved 33 patients just like that: They’d typically had seven to eight rounds of various treatments and were out of options. So researchers tried a recently developed approach that harnesses the immune system’s cancer-killing potential: CAR T-cell therapy. It involves removing immune system T-cells from a patient, then genetically altering them to be armed with chimeric antigen receptors, or CARs. That allows the T-cells to recognize and attack cancer cells once they are infused back into the blood, said senior researcher Dr. James Kochenderfer. CAR T-cell therapy is already approved for certain cases of leukemia and lymphoma — two other types of blood cancer. But the approach is not one-size-fits-all. CARs have to target a protein specific to the cancer, explained Kochenderfer, a scientist with the U.S. National Cancer Institute. In this study, his team used CARs that recognize a protein on multiple myeloma cells, called BCMA. The investigators found that… read on >